Clinical Trials Arena on MSN
Arrowhead begins dosing in Phase I/IIa trial for hyperlipidaemia
The therapy is designed to silence both PCSK9 and APOC3 genes simultaneously.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results